Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 12, 2013 - Issue 5
Submit an article Journal homepage
260
Views
9
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC

Raffaele Addeo“S. Giovanni di Dio” Hospital, ASL Napoli 2Nord, Oncology Unit, Frattamaggiore, Italy
,
Silvia ZappavignaSecond University of Naples, Department of Biochemistry, Biophysics and General Pathology, Via S.M. Costantinopoli, 16, 80138 Naples, Italy+00390815665871; +00390815665874+00390815665863michele.caraglia@[email protected]
,
Amalia LuceSecond University of Naples, Department of Biochemistry, Biophysics and General Pathology, Via S.M. Costantinopoli, 16, 80138 Naples, Italy+00390815665871; +00390815665874+00390815665863michele.caraglia@[email protected]
,
Sergio FacchiniSecond University of Naples, Department of Biochemistry, Biophysics and General Pathology, Via S.M. Costantinopoli, 16, 80138 Naples, Italy+00390815665871; +00390815665874+00390815665863michele.caraglia@[email protected]
&
Michele CaragliaSecond University of Naples, Department of Biochemistry, Biophysics and General Pathology, Via S.M. Costantinopoli, 16, 80138 Naples, Italy+00390815665871; +00390815665874+00390815665863michele.caraglia@[email protected]
Pages 729-740 | Published online: 08 Apr 2013

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Taku Fujimura, Takanori Hidaka, Yumi Kambayashi & Setsuya Aiba. (2019) BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Expert Opinion on Investigational Drugs 28:2, pages 143-148.
Read now
Tobias Weiss, Michael Weller & Patrick Roth. (2016) Immunological effects of chemotherapy and radiotherapy against brain tumors. Expert Review of Anticancer Therapy 16:10, pages 1087-1094.
Read now
Christophe Bedane, Marie-Thérèse Leccia, Bruno Sassolas, Bruno Bregman & Céleste Lebbé. (2013) Treatment patterns and outcomes in patients with advanced melanoma in France. Current Medical Research and Opinion 29:10, pages 1297-1305.
Read now

Articles from other publishers (6)

Raffaele Addeo, Giuseppe Lamberti, Giorgia Simonetti, Patrizia Iodice, Alfredo Marinelli, Liliana Montella, Salvatore Cappabianca, Paola Gaviani, Michele Caraglia, Salvatore Del Prete & Antonio Silvani. (2019) Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. CNS Oncology 8:2, pages CNS32.
Crossref
Michele Guida, Stefania Tommasi, Sabino Strippoli, Maria Iole Natalicchio, Simona De Summa, Rosamaria Pinto, Antonio Cramarossa, Anna Albano, Salvatore Pisconti, Michele Aieta, Ruggiero Ridolfi, Amalia Azzariti, Gabriella Guida, Vito Lorusso & Giusepe Colucci. (2018) The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer 18:1.
Crossref
Grace J. Young, Wenya Linda Bi, Winona W. Wu, Tanner M. Johanns, Gavin P. Dunn & Ian F. Dunn. (2017) Management of intracranial melanomas in the era of precision medicine. Oncotarget 8:51, pages 89326-89347.
Crossref
T Redmer, I Walz, B Klinger, S Khouja, Y Welte, R Schäfer & C Regenbrecht. (2017) The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis 6:1, pages e291-e291.
Crossref
Olga Venditti, Delia De Lisi, Marco Caricato, Damiano Caputo, Gabriella Teresa Capolupo, Chiara Taffon, Elisa Pagliara, Sofia Battisi, Anna Maria Frezza, Andrea Onetti Muda, Giuseppe Tonini & Daniele Santini. (2015) Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer 15:1.
Crossref
Wynand P. Roos, Steve Quiros, Andrea Krumm, Stephanie Merz, Olivier Jérôme Switzeny, Markus Christmann, Carmen Loquai & Bernd Kaina. (2014) B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Oncotarget 5:24, pages 12607-12620.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.